Almac Discovery has entered a research and licensing agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target.   Almac will receive $14.5 million upfront and will be eligible to receive as much as $349 million based certain milestones, as well as royalties on sales of multiple products based on Genentech targets.   Almac Discovery’s potent and selective small molecule inhibitors will be the starting poi...